Why Moderna Is the Biggest Winner From COVID Boosters So Far - Motley Fool
Food and Drug Administration (FDA) authorized boosters for the COVID-19 vaccine developed by Pfizer ( PFE ) and BioNTech ( BNTX ) for certain groups.
A little over two weeks ago, the FDA broadened its Emergency Use Authorization for the Pfizer-BioNTech and Moderna boosters to include all adults ages 18 and older.More booster doses of the Pfizer-BioNTech vaccine have been given than have been administered for the Moderna and J&J boosters.You'd expect that more people would have received the Pfizer-BioNTech booster.Also, many more individuals received the Pfizer-BioNTech vaccine initially than received the other two vaccines.A lot of those people chose to receive the booster of the same vaccine that they received for their primary series.
Second, Moderna is gaining more traction with boosters than Pfizer-BioNTech or J&J are.A little over 25% of the number of fully vaccinated individuals receiving the primary series of the Moderna vaccine have received Moderna boosters.
For those who initially received the J&J vaccine, 42.5% so far have gone with the Moderna booster versus 31.2% for a Pfizer-BioNTech booster and only 26.2% for a J&J booster. .
I suspect that preliminary data showing that a mix-and-match combination of the Pfizer-BioNTech primary series and a Moderna booster provides a higher efficacy could also be making a difference to some extent.Singapore's minister of health even recently recommended that citizens in the country who initially received the Pfizer-BioNTech vaccine get the Moderna booster.
has already purchased enough doses from Moderna to meet the demand, including boosters.
What really matters for Moderna is how strong the longer-term demand will be for its COVID-19 vaccine.